Work

Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials

Year: 2024

Type: article

Abstract: Selecting patients for phase I cancer trials is crucial to ensure a sufficient life expectancy. Frail patients, better suited for palliative care, should not be exposed to new drugs with minimal benefit. Enrolling patients at high risk of early death can jeopardize the study. Our analysis of two large precision medicine studies used tumor fraction from ctDNA to develop a predictive model, demonstrating notable predictive accuracy and aiding in patient selection.

Source: npj Precision Oncology

DOI: 10.1038/s41698-024-00685-9

Authors: Arnaud Bayle, Laila Belcaid, Sophie Cousin, Kilian Trin, Melissa Alame, Etienne Rouleau, Isabelle Soubeyran, Ludovic Lacroix, Laura Blouin, Damien Vasseur, Amandine Crombe, Simone Mathoulin-Pelissier, Jean-Charles Soria, Carine Bellera, Antoine Italiano

Institutions: Institut Gustave Roussy, Institut Bergonié, Inserm, Bordeaux Population Health, Centre d'Investigation Clinique Plurithématique de Bordeaux, Fondation Gustave Roussy, Université de Bordeaux, Centre Hospitalier Universitaire de Bordeaux

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,790

Funders: Institut Gustave-Roussy, Fondation Gustave Roussy

OpenAlex ID: W4403179218

FWCI: 1.38

Cites: 16

Cited by: 9

Related to: 10